Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Prognostic Marker Found for Oropharyngeal Cancer

No. 26 | 02/05/2013 | by Koh

In cancers of the oropharynx, a specific pattern of chemical tags in tumor cell DNA indicates a favorable prognosis. This so-called “epigenetic signature” predicts disease progression more reliably than previously used prognostic criteria. Patients with a predicted favorable prognosis could be treated less intensively. This was reported by scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital.

© dkfz.de

Cancers of the oropharynx are usually so-called squamous cell carcinomas, which originate from cells of the mucous membranes. Known risk factors for this disease include alcohol and cigarettes. However, the incidence is rising, even among people who neither drink nor smoke. “These patients frequently have an infection with cancer-causing types of human papillomaviruses (HPV)”, says Associate Professor (PD) Dr. Jochen Hess, who leads a junior research group at DKFZ and a research group at the Ear, Nose and Throat Hospital of Heidelberg University. “Up to 60 percent of squamous cell carcinomas of the oropharynx are positive for HPV16, the same one which also causes cancer of the cervix.”

Cancer researchers are particularly interested in the group of HPV-associated oropharyngeal tumors, because they take a much more favorable course than cases attributable to the classic risk factors. The majority of HPV-associated oropharyngeal cancers respond particularly well to radiotherapy and chemotherapy, which means that patients have a longer life expectancy. However, even among HPV-associated tumors there are exceptions where the disease progresses unfavorably. The molecular causes for this are unknown.

“Oncologists are therefore very interested in a marker that reliably identifies tumors with a favorable prognosis. These patients could be treated less intensively and side effects could thus be reduced considerably,” Jochen Hess explains. He had the idea that altered epigenetic tags in the tumor DNA might be a possible molecular cause of the varying courses the disease may take. “Tagging with methyl groups, in particular, has an impact on the activity of many genes and hence on a cell’s behavior,” says Hess.

In collaboration with colleagues led by Dr. Efterpi Kostareli and Dr. Dieter Weichenhan from DKFZ, clinicians from Heidelberg University Hospital and Leipzig University Hospital as well as from the University of Chicago, Hess’ team searched for differences in the methylation patterns of oropharyngeal cancer cells with and without HPV involvement. They found out that a very favorable disease progression correlated with a specific pattern of tags: Three specific genes are more active as a result of a mild methylation, while two others are silenced.

This result was first obtained in 100 tumor samples from Heidelberg and subsequently confirmed in tumor tissue of 120 other patients from Leipzig and Chicago. Four of the five affected genes regulate the retinoic acid metabolism, which has an impact on the growth, differentiation and death of cells. The researchers also proved that the epigenetic alterations did in fact have an impact on the biology of cancer cells: The amount of RNA copies of the five genes corresponded to what was expected due to the altered methylation of the respective gene.

The alterations in the epigenetic profile were found particularly often in patients with HPV infection. However, the study also identified HPV-negative tumor patients with the prognostically more favorable methylation pattern. Hence, disease progression can be predicted with a higher level of exactitude using the signature than by virus detection alone. “The signature can be tested right at first diagnosis and may help physicians differentiate patients who immediately need intensive chemotherapy or radiotherapy from those for whom less aggressive treatment regimens may be sufficient.”

Efterpi Kostareli, Dana Holzinger, Olga Bogatyrova, Thomas Hielscher, Gunnar Wichmann, Michaela Keck, Bernd Lahrmann, Niels Grabe, Christa Flechtenmacher, Christopher R. Schmidt, Tanguy Seiwert, Gerhard Dyckhoff, Andreas Dietz, Daniela Hoefler, Michael Pawlita, Axel Benner, Franz X. Bosch, Peter Plinkert, Christoph Plass, Dieter Weichenhan and Jochen Hess: HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas
Journal of Clinical Investigations 2013, DOI: 10.1172/JCI67010

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS